TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2837830

Group type: EXPERIMENTAL
Intervention: Adjuvant CAP chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone or in combination with radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative therapy (chemotherapy alone or combination with radiation) followed by adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapy directed at CNS disease
Number of subjects: 0
Study: 29608807

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) + Peripheral Nerve Field Stimulation (PNFS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Spinal Cord Stimulation (SCS) alone
Number of subjects: 50
Study: 28372326

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR) intervention group (IG) performing twelve sessions of CR over three months.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standardized cognitive training in the active control group (CG).
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG).
Number of subjects: 16
Study: 26215778

Group type: EXPERIMENTAL
Intervention: Postoperative Atrial Fibrillation (POAF)
Number of subjects: 398
Study: 23622913

Group type: EXPERIMENTAL
Intervention: Permanent percutaneous transvenous mitral annuloplasty (PTMA) device
Number of subjects: 43
Study: 21707327

Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Testosterone gel vs Placebo gel
Number of subjects: 100
Study: 18622011

Group type: EXPERIMENTAL
Intervention: Theater-based after-school program 'Ready. Set. ACTION!'
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 96
Study: 16443774

Group type: EXPERIMENTAL
Intervention: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in HNF-1beta mutation carriers
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in HNF-1alpha mutation carriers
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in control subjects
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-dose insulin (1.5 mU . kg(‐1) . min(‐1)) in all groups
Number of subjects: 18
Study: 14693773

Group type: EXPERIMENTAL
Intervention: Flicker light (12.5 Hz, 530‐600 nm, duration 20 seconds)
Number of subjects: 5
Study: 11467238

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined regimen of acetazolamide and dexamethasone (twice daily for 5 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (multivitamin)
Number of subjects: 24
Study: 9479673

Group type: EXPERIMENTAL
Intervention: Eye movement desensitization and reprocessing (EMDR) (n = 10)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Biofeedback‐assisted relaxation (n = 13)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Routine clinical care (control) (n = 12)
Number of subjects: 35
Study: 7802981

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 41
Study: 3047214

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (Healthy subjects)
Number of subjects: 73
Study: 31795883

Group type: EXPERIMENTAL
Intervention: Nursing intervention using Orem's self-care model for eight sessions of 45-60 minutes
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study: 29135576

Group type: EXPERIMENTAL
Intervention: Assisted partner services (aPS)
Number of subjects: 500000

Group type: COMPARATOR
Intervention: Program scenario of aPS
Number of subjects: 500000

Group type: COMPARATOR
Intervention: Task-shifting scenario of aPS
Number of subjects: 500000
Study: 28231975

Group type: EXPERIMENTAL
Intervention: Foraminal enlargement (FE) with a continuous rotary system
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nonforaminal enlargement (NFE)
Number of subjects: 70
Study: 26147369

Group type: EXPERIMENTAL
Intervention: Virosomal vaccine H5N1 (NIBRG‐14) with Matrix M adjuvant (1.5, 7.5 or 30 μg HA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Virosomal vaccine H5N1 (NIBRG‐14) without Matrix M adjuvant (30 μg HA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vaccine (with or without Matrix M)
Number of subjects: 60
Study: 24274213

Group type: EXPERIMENTAL
Intervention: Lumbar drains (LDs)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No lumbar drains (LDs)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Increased intracranial pressure (ICP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Increased ICP (both groups)
Number of subjects: 150
Study: 21952595

Group type: EXPERIMENTAL
Intervention: Nerve stimulation technique (NS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Loss of resistance technique (LOR)
Number of subjects: 30
Study: 18469018

Group type: EXPERIMENTAL
Intervention: Standardized training program (n=24)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 mg rosiglitazone once daily (n=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 60
Study: 12565082

Group type: EXPERIMENTAL
Intervention: nisoldipine-ER (20 to 40 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: amlodipine (5 to 10 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: nisoldipine-ER
Number of subjects: 120

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: nisoldipine-ER and amlodipine
Number of subjects: 120
Study: 9457948

Group type: EXPERIMENTAL
Intervention: Alloplastic barrier material
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Autologous peritoneal transplants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Visceral peritoneum injury
Number of subjects: 40
Study: 7698380

Group type: EXPERIMENTAL
Intervention: Oxytocin dose increments at 20-min intervals
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin dose increments at 60-min intervals
Number of subjects: 100
Study: 2693231

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg nocte)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Sucralfate (1 g tds)
Number of subjects: 363
Study: 356245

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren) 125 mg daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31726081

Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) synchronized with gait cycle frequency
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study: 31647695

Group type: EXPERIMENTAL
Intervention: Decision Aid
Number of subjects: 29
Study: 27994091

Group type: COMPARATOR
Intervention: Etanercept (E) therapy
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Triple therapy (T)
Number of subjects: 353
Study: 25804278

Group type: EXPERIMENTAL
Intervention: Virgin olive oil (OO) diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Palm olein (PO) diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Coconut oil (CO) diet
Number of subjects: 45

Group type: COMPARATOR
Intervention: Thrombogenicity indices and cell adhesion molecules
Number of subjects: 45
Study: 23482999

Group type: EXPERIMENTAL
Intervention: 1% mepivacaine (0.9 ml injected)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 16
Study: 22610812

Group type: EXPERIMENTAL
Intervention: Sniffing position
Number of subjects: 400

Group type: COMPARATOR
Intervention: Simple head extension
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study: 19841761

Group type: COMPARATOR
Intervention: Single Bond 2 (SB2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clearfil SE Bond (CSE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Adper Prompt (ADP)
Number of subjects: 40
Study: 16895768

Group type: EXPERIMENTAL
Intervention: CFS patients (n = 30)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control patients (n = 96)
Number of subjects: 30
Study: 15645871

Group type: EXPERIMENTAL
Intervention: Sonicare Advance power toothbrush
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 40
Study: 11358679

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9014960

Group type: COMPARATOR
Intervention: Training once a week (1x/wk, n = 16)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Training twice a week (2x/wk, n = 17)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Training three times a week (3x/wk, n = 15)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (C, n = 10)
Number of subjects: 58
Study: 8204875

Group type: EXPERIMENTAL
Intervention: Cranial radiotherapy (cRT) plus prolonged triple intrathecal (IT) therapy with methotrexate (MTX), cytarabine, and prednisone.
Number of subjects: 93

Group type: COMPARATOR
Intervention: No cranial radiotherapy (cRT) but prolonged triple IT therapy.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Neither cRT nor prolonged triple IT therapy.
Number of subjects: 93
Study: 29804283

Group type: EXPERIMENTAL
Intervention: R:C ratio of 40:60
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: R:C ratio of 80:20
Number of subjects: 40

Group type: COMPARATOR
Intervention: LRC inclusion
Number of subjects: 40
Study: 27274331

Group type: EXPERIMENTAL
Intervention: Video podcasts
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Written handouts
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison of podcasts vs handouts
Number of subjects: 41
Study: 23948001

Group type: EXPERIMENTAL
Intervention: Motivational tobacco cessation treatment combined with nicotine replacement
Number of subjects: 224

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 224
Study: 22329473

Group type: EXPERIMENTAL
Intervention: Memantine (starting dose of 5 mg increased up to 20 mg over four weeks, then stable dose of 20 mg from four to eight weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (matching pill)
Number of subjects: 29
Study: 20151970

Group type: EXPERIMENTAL
Intervention: bupropion SR 150 mg/daily
Number of subjects: 232

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 232
Study: 19375168

Group type: EXPERIMENTAL
Intervention: Intravitreal perfluoropropane (C3F8) gas injection (group A)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV) with intraocular C3F8 gas tamponade (group B)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with concomitant internal limiting membrane (ILM) peeling
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy without ILM peeling
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Postoperative best-corrected visual acuity
Number of subjects: 231
Study: 16974189

Group type: EXPERIMENTAL
Intervention: bupropion XL (300-450 mg/d)
Number of subjects: 348

Group type: COMPARATOR
Intervention: venlafaxine XR (150-225 mg/d)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: bupropion XL
Number of subjects: 348

Group type: COMPARATOR
Intervention: venlafaxine XR
Number of subjects: 348
Study: 12764337

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine with ibuprofen
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 11195030

Group type: EXPERIMENTAL
Intervention: 10 microg LPS
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 40 microg LPS
Number of subjects: 7

Group type: COMPARATOR
Intervention: 0 microg LPS (saline treatment)
Number of subjects: 7
Study: 9068541

Group type: EXPERIMENTAL
Intervention: Acute caffeine ingestion
Number of subjects: 0
Study: 8349477

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 3539741

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 30098076

Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg/d orally from 3 days before surgery to 3 days after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle treatment in rats
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral placebo treatment in patients
Number of subjects: 60
Study: 26223941

Group type: EXPERIMENTAL
Intervention: Teduglutide (TED) 0.05 mg/kg daily subcutaneous
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study: 24258773

Group type: EXPERIMENTAL
Intervention: IV famotidine 12 mg/m²
Number of subjects: 24

Group type: COMPARATOR
Intervention: IV ranitidine 60 mg/m²
Number of subjects: 24
Study: 22321909

Group type: EXPERIMENTAL
Intervention: Propranolol (noradrenergic antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20147856

Group type: EXPERIMENTAL
Intervention: Oral S-1 (60 mg/m/d, twice a day) from days 1 to 14 with gemcitabine (1000 mg/m/d) on days 1 and 8 (arm A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral S-1 (60 mg/m/d, twice a day) from days 1 to 14 with gemcitabine (1000 mg/m/d) on days 8 and 15 (arm B)
Number of subjects: 80
Study: 18528312

Group type: EXPERIMENTAL
Intervention: Ossiculoplasty (OP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intact native chain reconstruction (INCR)
Number of subjects: 39
Study: 16115299

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 12501031

Group type: EXPERIMENTAL
Intervention: Consumption of medical television drama
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Practical knowledge of cardiopulmonary resuscitation techniques
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Interaction of drama consumption and practical knowledge
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Practical knowledge of basic cardiopulmonary resuscitation techniques
Number of subjects: 820
Study: 10525698

Group type: EXPERIMENTAL
Intervention: STG-endobutton
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (BTB autograft)
Number of subjects: 14
Study: 8749732

Group type: EXPERIMENTAL
Intervention: Turbo spin-echo (TSE) T2-weighted pulse sequences
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional spin-echo (CSE) T2-weighted images
Number of subjects: 78

Group type: COMPARATOR
Intervention: Gradient-echo (GE) sequence
Number of subjects: 78
Study: 2029414

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: External-beam radiation therapy
Number of subjects: 0
Study: 7299867

Group type: EXPERIMENTAL
Intervention: 1 gm/6 hours cefamandole
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31931924

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (20 ml 0.5% bupivacaine in 480 ml normal saline)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal saline (500 ml)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 110
Study: 31640736

Group type: EXPERIMENTAL
Intervention: Betaine and folic acid
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 27767991

Group type: EXPERIMENTAL
Intervention: AZD3293 (15 mg QD)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AZD3293 (50 mg QD)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AZD3293 (≥5 mg single dose)
Number of subjects: 47
Study: 25899791

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg, single oral dose)
Number of subjects: 40
Study: 24042024

Group type: EXPERIMENTAL
Intervention: Any oral NSAIDs
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAIDs
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 4203

Group type: COMPARATOR
Intervention: Highest users of NSAIDs
Number of subjects: 4203

Group type: COMPARATOR
Intervention: Highest users of non-aspirin NSAIDs
Number of subjects: 4203

Group type: COMPARATOR
Intervention: Highest users of low-dose aspirin
Number of subjects: 4203
Study: 20602474

Group type: EXPERIMENTAL
Intervention: Preoperative coronary artery revascularization (PR)
Number of subjects: 109

Group type: COMPARATOR
Intervention: No preoperative coronary artery revascularization (no PR)
Number of subjects: 109

Group type: COMPARATOR
Intervention: No PR
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Anterior ischemia on preoperative imaging
Number of subjects: 109
Study: 19873914

Group type: EXPERIMENTAL
Intervention: Scalp point injection of 0.5‐1 mL brain protein hydrolysate into acupoints (Baihui (GV 20), Fengchi (GB 20), motor area)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous drip of 10 mL brain protein hydrolysate
Number of subjects: 120
Study: 18294442

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg every 12 h for 10 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (100 mg every 6 h for 10 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) (160/800 mg every 12 h for 10 days)
Number of subjects: 61
Study: 15591651

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at 10 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11204663

Group type: EXPERIMENTAL
Intervention: Oxaliplatin combined with fluorouracil (5‐FU)/leucovorin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin as monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin combined with 5‐FU and leucovorin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin in advanced colorectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NCCTG N9741 trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NCCTG N9841 trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSABP C‐07 adjuvant trial
Number of subjects: 0
Study: 9306144

Group type: EXPERIMENTAL
Intervention: Acoustic Quantification (AQ)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Doppler echocardiography
Number of subjects: 16
Study: 8100910

Group type: EXPERIMENTAL
Intervention: IIIB-rgp120/HIV-1 300 micrograms
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: IIIB-rgp120/HIV-1 100 micrograms
Number of subjects: 28

Group type: COMPARATOR
Intervention: Alum adjuvant alone
Number of subjects: 28
Study: 3555050

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Beta-lactam antibiotics
Number of subjects: 23
Study: 31171879

Group type: EXPERIMENTAL
Intervention: Dabrafenib, trametinib, and pembrolizumab
Number of subjects: 15
Study: 28596447

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy plus IV r‐tPA
Number of subjects: 108

Group type: COMPARATOR
Intervention: IV r‐tPA alone
Number of subjects: 108
Study: 25661122

Group type: EXPERIMENTAL
Intervention: 1.25 D toric IOL
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 1.25 D, 2.00 D, and 2.75 D toric IOLs (aggregate)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Nontoric accommodating IOL (Crystalens)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Toric IOL
Number of subjects: 128
Study: 23827859

Group type: EXPERIMENTAL
Intervention: Xpert® MTB/RIF test on pleural fluid
Number of subjects: 67
Study: 21872935

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg)
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.3 mg)
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Control treatment (verteporfin photodynamic therapy [PDT] and sham intravitreal injections)
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1298
Study: 19482341

Group type: EXPERIMENTAL
Intervention: 4250 IU/day of parnaparin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 6400 IU/day of parnaparin
Number of subjects: 66
Study: 17274862

Group type: EXPERIMENTAL
Intervention: Cocaine 4% solution
Number of subjects: 108

Group type: COMPARATOR
Intervention: Tetracaine 2% plus adrenaline
Number of subjects: 108
Study: 15483279

Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 345

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 345
Study: 12546311

Group type: EXPERIMENTAL
Intervention: Low-dose oral granisetron plus intravenous dexamethasone (gran/dex)
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-dose metoclopramide plus intravenous dexamethasone (met/dex)
Number of subjects: 24
Study: 10051936

Group type: EXPERIMENTAL
Intervention: Endotracheal lidocaine (0.4 ml lidocaine 8% spray)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (32 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Isoflurane 3% (no pretreatment)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (isoflurane maintained at 1.0%)
Number of subjects: 72
Study: 7981577

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens opposed by medrogestone
Number of subjects: 43
Study: 2513143

Group type: EXPERIMENTAL
Intervention: Flecainide (median dose 300 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 30188943

Group type: EXPERIMENTAL
Intervention: Alcohol use disorder (AUD) cohort
Number of subjects: 11639

Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 11639
Study: 28421732

Group type: EXPERIMENTAL
Intervention: Absolute fluid restriction (AR)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Relative volume redistribution (RR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both AR and RR
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pringle maneuver
Number of subjects: 34
Study: 25747680

Group type: EXPERIMENTAL
Intervention: MDD group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30